DRTS קצב צמיחת רווח למניה בשנה הנוכחית alphatau.com

Unique patents for alpha therapy create a powerful defensive moat for Alpha Tau Medical (DRTS). The 12-month EPS growth rate visualizes the impact of this factor, with the value holding at -81.40. However, narrow specialization and the complexities of technology implementation are hindering expansion. Stability is ensured by strategic outsourcing of mechanics while maintaining full control over radiation developments.

This indicator measures the year-over-year dynamics of net earnings per share, allowing for an assessment of business scaling rates relative to the previous period. Analyzing the annual change in earnings per share is critical for Alpha Tau Medical (DRTS), as the absence of stable cash flows and the current stage of technology implementation make any positive trend a signal of exiting the pure investment phase.